DOCMORRIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.55 CHF | +3.63% |
|
+4.58% | +16.00% |
| Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
| Apr. 19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
ETFs positioned on DocMorris AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 152 M€ | -3.56% | - | |
| 0.00% | 26 M€ | -4.70% | - |
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Sector
Drug Retailers
Calendar
2024-05-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
85.55
CHF
Average target price
99.24
CHF
Spread / Average Target
+16.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 1.1B | |
| -31.97% | 10.84B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -30.42% | 6.06B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- ROSE Stock
- Funds and ETFs DocMorris AG
